Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.

A, Zanchetti; S, Julius; S, Kjeldsen; GT, McInnes; T, Hua; M, Weber; JH, Laragh; F, Plat; E, Battegay; C, Calvo-Vargas; A, Cieśliński; JP, Degaute; NJ, Holwerda; J, Kobalava; OL, Pedersen; FP, Rudyatmoko; KC, Siamopoulos; O, Störset

doi:10.1097/01.hjh.0000249692.96488.46

Public

Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.

Shared by NobleBlocks on Nov 1, 2006 • 12:00 AM UTC

Authors:

Zanchetti A

Julius S

Kjeldsen S

Abstract

<h4>Background</h4>In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pressure reductions wer...

Discussions